Non-alcoholic fatty liver disease: When to intervene and with what

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 15, Issue 2, 2015, Pages 186-190

  Than, Nwe Ni ^a,b   Newsome, Philip N ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cirrhosis; Insulin resistance; Non alcoholic fatty liver disease; Obesity; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; METFORMIN;

ARTICLE; BARIATRIC SURGERY; END STAGE LIVER DISEASE; GENE FREQUENCY; HUMAN; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; WEIGHT REDUCTION; FEMALE; LIFESTYLE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

BARIATRIC SURGERY; FEMALE; HUMANS; LIFE STYLE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; WEIGHT LOSS;

EID: 84927933666     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.15-2-186     Document Type: Article

References (28)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
2. Leite NC, Salles GF, Araujo ALE et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113-9.
3. Kallwitz ER, Kumar M, Aggarwal R et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008;53:1358-63.
4. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of nonalcoholic fatty liver disease. QJM 2010;103:71-83.
5. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
6. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:645-55.
7. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
8. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
9. Armstrong MJ, Houlihan DD, Bentham L et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234-40.
10. McPherson S, Stewart SF, Henderson E et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265-9.
11. McPherson S, Anstee QM, Henderson E et al. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013;25:652-8.
12. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic s pectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
13. Petta S, Vanni E, Bugianesi E et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2014, epub ahead of print.
14. Academy of Medical Royal Colleges. Measuring up: the medical profession's prescription for the nation's obesity crisis. London: Academy of Medical Royal Colleges, 2013.
15. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010;52:370-81.
16. Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
17. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.
18. Sanyal AJ, Chalasani N, Kowley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
19. Armstrong MJ, Houlihan DD, Rowe IA et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013;37:234-42.
20. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
21. Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol 2012;26:353-7.
22. Lavine JE, Schwimmer JB, Van Natta ML et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68.
23. Chalasani NP, Sanyal AJ, Kowdley KV et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009;30:88-96.
24. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690-5.
25. Lewis JH, Mortensen ME, Zweig S et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63.
26. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
27. Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532-40.
28. Houlihan DD, Armstrong MJ, Davidov Y et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl 2011;17:1292-8.